{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:47:55Z","timestamp":1782974875599,"version":"3.54.5"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Organization for Health Research and Development","award":["171002102"],"award-info":[{"award-number":["171002102"]}]},{"name":"Netherlands Heart Foundation","award":["2012T051"],"award-info":[{"award-number":["2012T051"]}]},{"name":"Dutch Organization for Health Research and Development","award":["90700354"],"award-info":[{"award-number":["90700354"]}]},{"name":"Dutch Organization for Health Research and Development","award":["171002102"],"award-info":[{"award-number":["171002102"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["LE 3660\/1-1 KFO 252"],"award-info":[{"award-number":["LE 3660\/1-1 KFO 252"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.pharmthera.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T13:37:15Z","timestamp":1437917835000},"page":"120-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Pharmacological treatment of aldosterone excess"],"prefix":"10.1016","volume":"154","author":[{"given":"Jaap","family":"Deinum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels P.","family":"Riksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques W.M.","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.07.006_bb0005","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0010","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1530\/EJE-14-0585","article-title":"Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma","volume":"172","author":"Amar","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0015","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0020","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/HYPERTENSIONAHA.107.096925","article-title":"Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate","volume":"50","author":"Armanini","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0025","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008169.pub2","article-title":"Spironolactone for hypertension","author":"Batterink","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0040","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0045","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-13-0263","article-title":"Regulation of aldosterone secretion: from physiology to disease","volume":"168","author":"Beuschlein","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0050","doi-asserted-by":"crossref","first-page":"31283","DOI":"10.1074\/jbc.M504098200","article-title":"A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor","volume":"280","author":"Bledsoe","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0055","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cphy.c130037","article-title":"Regulation of aldosterone synthesis and secretion","volume":"4","author":"Bollag","year":"2014","journal-title":"Compr Physiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0060","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cpt197722114","article-title":"Diuretic therapies in low renin and normal renin essential hypertension","volume":"22","author":"Brooks","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0070","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0075","doi-asserted-by":"crossref","first-page":"88S","DOI":"10.1093\/ajh\/1.3.88S","article-title":"The absence of long-term therapeutic effect of calcium channel blockade in the primary aldosteronism of adrenal adenomas","volume":"1","author":"Bursztyn","year":"1988","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0080","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0090","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0100","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/1440-1681.12145","article-title":"Aldosterone, organ damage and dietary salt","volume":"40","author":"Catena","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","article-title":"Eplerenone is not superior to older and less expensive aldosterone antagonists","volume":"125","author":"Chatterjee","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"Colussi","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0120","first-page":"213","article-title":"Suppression of plasma renin activity in primary aldosteronism","volume":"190","author":"Conn","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0125","first-page":"215","article-title":"Primary aldosteronism: a new clinical entity","volume":"68","author":"Conn","year":"1955","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2007-0030","article-title":"A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function","volume":"29","author":"Connell","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0140","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","article-title":"The effects of spironolactone and chlorthalidone on arterial pressure","volume":"1","author":"Cranston","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0145","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0150","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.mce.2011.07.019","article-title":"Non-genomic actions of aldosterone: from receptors and signals to membrane targets","volume":"350","author":"Dooley","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0160","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(88)90742-8","article-title":"Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor","volume":"2","author":"Edwards","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0165","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","article-title":"Human adipocytes secrete mineralocorticoid-releasing factors","volume":"100","author":"Ehrhart-Bornstein","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0170","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0175","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.amjhyper.2007.03.012","article-title":"Adiponectin and insulin sensitivity in primary aldosteronism","volume":"20","author":"Fallo","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsbmb.2013.02.012","article-title":"Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity","volume":"137","author":"Feraco","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt197721162","article-title":"Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension","volume":"21","author":"Ferguson","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","article-title":"Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma","volume":"64","author":"Fernandes-Rosa","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0195","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","article-title":"Role of mineralocorticoid receptor antagonists in cardiovascular disease","volume":"116","author":"Ferrario","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0002-8703(78)90132-1","article-title":"The treatment of low-renin (\"primary\") hyperaldosteronism","volume":"96","author":"Ferriss","year":"1978","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0205","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0210","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1210\/jc.2012-3934","article-title":"Aldosterone excess impairs first phase insulin secretion in primary aldosteronism","volume":"98","author":"Fischer","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2265.2011.04243.x","article-title":"Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry","volume":"76","author":"Fischer","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0220","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-12-0631","article-title":"Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism","volume":"168","author":"Fourkiotis","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0230","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCIMAGING.112.974576","article-title":"Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study","volume":"5","author":"Freel","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0235","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/er.2005-0004","article-title":"The nongenomic actions of aldosterone","volume":"26","author":"Funder","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0245","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0250","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0255","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2008.10.029","article-title":"Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology","volume":"301","author":"Funder","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0260","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","article-title":"Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated","volume":"242","author":"Funder","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0265","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0270","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2009-2521","article-title":"Aldosterone production and insulin resistance in healthy adults","volume":"95","author":"Garg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-131-2-199907200-00005","article-title":"Medical management of aldosterone-producing adenomas","volume":"131","author":"Ghose","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0285","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","article-title":"Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study","volume":"25","author":"Giacchetti","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0290","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0295","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cphy.c130044","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0300","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5664\/jcsm.27878","article-title":"Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension","volume":"6","author":"Gonzaga","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0305","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.1982.9","article-title":"Amiloride in primary hyperaldosteronism","volume":"31","author":"Griffing","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0310","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","article-title":"GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone","volume":"57","author":"Gros","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0315","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1210\/en.2012-1339","article-title":"Minireview: aldosterone biosynthesis: electrically gated for our protection","volume":"153","author":"Guagliardo","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0320","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tem.2012.09.004","article-title":"Aldosterone and cardiovascular disease: the heart of the matter","volume":"24","author":"He","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0330","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1097\/HJH.0b013e32834a4c75","article-title":"Aldosterone as a modulator of immunity: implications in the organ damage","volume":"29","author":"Herrada","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0335","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.1980.42","article-title":"Spironolactone and amiloride in hypertensive patients with and without aldosterone excess","volume":"27","author":"Hoefnagels","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0340","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/bcp.12012","article-title":"Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis","volume":"75","author":"Hu","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0345","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1021\/jm401430e","article-title":"Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases","volume":"57","author":"Hu","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0350","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0355","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"Ivanes","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0360","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0365","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/HJH.0b013e32835b71d6","article-title":"Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension","volume":"31","author":"Jansen","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0370","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0375","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/01.CIR.0000030935.89559.04","article-title":"Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure","volume":"106","author":"Jorde","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0380","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0385","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1677\/ERC-08-0094","article-title":"Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas","volume":"15","author":"Karagiannis","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0390","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism","volume":"9","author":"Karagiannis","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0395","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0400","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1210\/jc.2010-0823","article-title":"Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism","volume":"95","author":"Kontak","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0405","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2265.1977.tb01307.x","article-title":"Amiloride in the treatment of primary hyperaldosteronism and essential hypertension","volume":"7","author":"Kremer","year":"1977","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0410","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0415","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jpsychires.2012.08.025","article-title":"Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone","volume":"46","author":"Kunzel","year":"2012","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0420","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/heartjnl-2014-305673","article-title":"Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms","volume":"100","author":"Lee","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0425","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0430","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0435","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2011.12.003","article-title":"Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma","volume":"221","author":"Lin","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0445","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/HJH.0b013e3283550f93","article-title":"Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism","volume":"30","author":"Lin","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0450","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-12-0912","article-title":"Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion","volume":"168","author":"Lucatello","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0455","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.2012.170","article-title":"Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury","volume":"82","author":"Luther","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0460","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.mce.2011.06.026","article-title":"Non-adrenal synthesis of aldosterone: a reality check","volume":"350","author":"MacKenzie","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0465","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/jhh.2013.70","article-title":"Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study","volume":"28","author":"Mark","year":"2014","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0470","first-page":"963","article-title":"Mineralocorticoid receptor antagonists and endothelial function","volume":"9","author":"Maron","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0475","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0480","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2011.06.014","article-title":"Mineralocorticoid receptors in vascular function and disease","volume":"350","author":"McCurley","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0485","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ncpendmet0676","article-title":"Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist","volume":"4","author":"McManus","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0490","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.steroids.2014.05.017","article-title":"Mineralocorticoid receptor signaling: crosstalk with membrane receptors and other modulators","volume":"91","author":"Meinel","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0495","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0500","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0505","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0510","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/HJH.0b013e3282861fa4","article-title":"A possible association between primary aldosteronism and a lower beta-cell function","volume":"25","author":"Mosso","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0515","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0520","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0525","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bjs.9744","article-title":"Systematic review of surgery and outcomes in patients with primary aldosteronism","volume":"102","author":"Muth","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0530","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-60-5-896","article-title":"Therapeutic effect of calcium channel blockade in primary aldosteronism","volume":"60","author":"Nadler","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MNH.0b013e32834fb25b","article-title":"Extrarenal effects of aldosterone","volume":"21","author":"Nguyen Dinh Cat","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0540","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0545","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.mce.2011.07.020","article-title":"Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: an overview","volume":"350","author":"Odermatt","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0550","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/clpt.1985.206","article-title":"New insights into the pharmacokinetics of spironolactone","volume":"38","author":"Overdiek","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0555","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/clpt.1986.219","article-title":"Influence of food on the bioavailability of spironolactone","volume":"40","author":"Overdiek","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0560","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0565","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.tem.2015.01.007","article-title":"Emerging cardiovascular indications of mineralocorticoid receptor antagonists","volume":"26","author":"Parviz","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0570","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1210\/jc.2011-0354","article-title":"Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study","volume":"96","author":"Pimenta","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0575","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0580","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0585","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0590","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0595","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0600","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0605","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German Conn's registry","volume":"60","author":"Reincke","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0610","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0615","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-14-0444","article-title":"Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy","volume":"172","author":"Riester","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0620","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0625","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","article-title":"Pathophysiological effects of aldosterone in cardiovascular tissues","volume":"12","author":"Rocha","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0630","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjhyper.2005.08.011","article-title":"Cardiac consequences of aldosterone excess in human hypertension","volume":"19","author":"Rossi","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0635","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrendo.2011.76","article-title":"A comprehensive review of the clinical aspects of primary aldosteronism","volume":"7","author":"Rossi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0640","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0645","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0650","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0655","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V86980","article-title":"1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure","volume":"8","author":"Rossier","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0660","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000371497","article-title":"Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy","volume":"40","author":"Ruilope","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0665","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"6","author":"Saruta","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0670","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0675","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","article-title":"Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy","volume":"31","author":"Schumacher","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0680","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0685","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ki.2011.505","article-title":"Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms","volume":"81","author":"Shavit","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0690","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/01.HYP.29.3.723","article-title":"Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism","volume":"29","author":"Shigematsu","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0695","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0700","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(52)91551-1","article-title":"Secretion of a salt-retaining hormone by the mammalian adrenal cortex","volume":"2","author":"Simpson","year":"1952","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0705","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1152\/physrev.00030.2003","article-title":"Control of aldosterone secretion: a model for convergence in cellular signaling pathways","volume":"84","author":"Sp\u00e4t","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0710","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ackd.2014.10.003","article-title":"Outcomes of drug-based and surgical treatments for primary aldosteronism","volume":"22","author":"Steichen","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jc.2014-3663","article-title":"Update in primary aldosteronism","volume":"100","author":"Stowasser","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0720","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.hlc.2013.01.006","article-title":"The renaissance of primary aldosteronism: what has it taught us?","volume":"22","author":"Stowasser","year":"2013","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0725","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1210\/jc.2008-2803","article-title":"Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience","volume":"94","author":"Sukor","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0730","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.21.6.929","article-title":"Vasodilation to acetylcholine in primary and secondary forms of human hypertension","volume":"21","author":"Taddei","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0735","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/BF03347840","article-title":"Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan","volume":"18","author":"Takeda","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0740","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semnephrol.2014.04.005","article-title":"Comparison of agents that affect aldosterone action","volume":"34","author":"Tamargo","year":"2014","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0745","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/en.2013-1944","article-title":"Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas","volume":"155","author":"Tauber","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0750","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00005344-198803000-00008","article-title":"Nifedipine does not blunt the aldosterone and cardiovascular response to angiotensin II and potassium infusion in hypertensive patients","volume":"11","author":"Terzoli","year":"1988","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0755","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pharmthera.2013.11.006","article-title":"The cardioprotective effects of mineralocorticoid receptor antagonists","volume":"142","author":"van den Berg","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0760","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCHEARTFAILURE.113.000530","article-title":"Race influences the safety and efficacy of spironolactone in severe heart failure","volume":"6","author":"Vardeny","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0765","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0770","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0775","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0780","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0785","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0790","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0795","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0800","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0805","doi-asserted-by":"crossref","first-page":"H555","DOI":"10.1152\/ajpheart.00847.2010","article-title":"Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension","volume":"300","author":"Xue","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0810","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2011-2563","article-title":"Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy","volume":"97","author":"Yoneda","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0815","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1527-5299.2005.03722.x","article-title":"Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure","volume":"11","author":"Yoshida","year":"2005","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0820","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","article-title":"Primary aldosteronism: renaissance of a syndrome","volume":"66","author":"Young","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0825","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0835","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1530\/JOE-14-0597","article-title":"An update on novel mechanisms of primary aldosteronism","volume":"224","author":"Zennaro","year":"2015","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0840","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11010-013-1672-0","article-title":"Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway","volume":"380","author":"Zhu","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmthera.2015.07.006_bb0845","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.coph.2012.12.007","article-title":"Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications","volume":"13","author":"Zwadlo","year":"2013","journal-title":"Curr Opin Pharmacol"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:14:25Z","timestamp":1748542465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":169,"alternative-id":["S0163725815001448"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.07.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatment of aldosterone excess","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}